Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $4.2 million.

  • Monte Rosa Therapeutics' Change in Accured Expenses rose 8007.73% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 5844.59%. This contributed to the annual value of $4.2 million for FY2024, which is 1762.72% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Change in Accured Expenses stood at $4.2 million for Q3 2025, which was up 8007.73% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Change in Accured Expenses ranged from a high of $4.2 million in Q3 2025 and a low of -$3.9 million during Q1 2024
  • For the 3-year period, Monte Rosa Therapeutics' Change in Accured Expenses averaged around $623454.5, with its median value being $2.0 million (2024).
  • In the last 5 years, Monte Rosa Therapeutics' Change in Accured Expenses surged by 18681.15% in 2024 and then plummeted by 22089.04% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Change in Accured Expenses stood at $1.3 million in 2023, then skyrocketed by 186.81% to $3.7 million in 2024, then rose by 13.44% to $4.2 million in 2025.
  • Its Change in Accured Expenses stands at $4.2 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$2.6 million for Q1 2025.